Safety and Efficacy Study of Exenatide Once Weekly in Adolescents with Type 2 Diabetes
Study identifier:BCB114
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Recruitment on Hold
Official Title
A Phase 3, Double-Blind, Placebo-Controlled, Randomized, Multi-Center Study to Assess the Safety and Efficacy of Exenatide Once Weekly in Adolescents with Type 2 Diabetes
Medical condition
adolescent type 2 diabetes
Phase
Phase 3
Healthy volunteers
No
Study drug
Exenatide Once Weekly, Placebo
Sex
All
Actual Enrollment
100
Study type
Interventional
Age
10 Years - 17 Years
Date
Study Start Date: 01 Nov 2011
Estimated Primary Completion Date: 01 Jan 2017
Estimated Study Completion Date: 01 Jan 2017
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Mar 2015 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
AstraZeneca
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: EQW Exenatide once weekly | Drug: Exenatide Once Weekly 2 mg exenatide once weekly Other Name: BYDUREON |
| Placebo Comparator: Placebo | Drug: Placebo Placebo |
Contacts
Investigators
Principal Investigator
Senior Vice President Research and Development
Amylin Pharmaceuticals, Inc.
